Docetaxel induced cardiotoxicity

Target therapies-induced Cardiotoxicity

Target therapies have become an important component of the treatment of many cancers, with significant evidence of a gain in survival in their use, but at the same time, with increasing concern about their ability to cause a wide spectrum of secondary cardiovascular adverse events (left ventricular dysfunction, heart failure, hypertension, ischaemic heart disease, QT prolongation, sudden cardia...

Trastuzumab-induced cardiotoxicity.

PURPOSE/OBJECTIVES To review trastuzumab-related cardiotoxic effects in the breast cancer adjuvant setting, present a system for pretreatment screening for cardiovascular risk factors, describe monitoring recommendations, provide a tool to facilitate adherence to monitoring guidelines, and discuss implications for patient education. DATA SOURCES Literature regarding cardiotoxicity and trastuz...

Deconvoluting Kinase Inhibitor Induced Cardiotoxicity

Many drugs designed to inhibit kinases have their clinical utility limited by cardiotoxicity-related label warnings or prescribing restrictions. While this liability is widely recognized, designing safer kinase inhibitors (KI) requires knowledge of the causative kinase(s). Efforts to unravel the kinases have encountered pharmacology with nearly prohibitive complexity. At therapeutically relevan...

Docetaxel-induced photolichenoid eruption

A 58-year-old man presented with complaints of blackish discoloration of forearms and face of five months duration. The lesions occurred episodically after taking anti-cancer medications, each episode lasting for two weeks. Histopathology confirmed a lichenoid eruption. Photolichenoid eruption to docetaxel is a dermatological adverse effect not reported in literature earlier.

[Docetaxel-induced psoriasis].